Frdrique Menzaghi - Cara Therapeutics Chief RD
| 69C Stock | EUR 4.84 0.00 0.00% |
Insider
Frdrique Menzaghi is Chief RD of Cara Therapeutics
| Age | 57 |
| Phone | 203 406 3700 |
| Web | https://www.caratherapeutics.com |
Cara Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.2558) % which means that it has lost $0.2558 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.4516) %, meaning that it generated substantial loss on money invested by shareholders. Cara Therapeutics' management efficiency ratios could be used to measure how well Cara Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Marcus Schindler | Novo Nordisk AS | 57 | |
| Jerh Collins | Moderna | N/A | |
| Marcello Damiani | Moderna | 49 | |
| Melissa Moore | Moderna | N/A | |
| Robert Langer | Moderna | 73 | |
| Steffen Hoffmann | Mercedes Benz Group AG | 53 | |
| Mark Dehring | CSL Limited | N/A | |
| Wilfried Freudenberg | CSL Limited | N/A | |
| Britta Seeger | Mercedes Benz Group AG | 54 | |
| Thomas Laubert | Mercedes Benz Group AG | 50 | |
| Ola Kallenius | Mercedes Benz Group AG | 54 | |
| Sean Marett | BioNTech SE | 58 | |
| Paul McKenzie | CSL Limited | 57 | |
| Renata Brungger | Mercedes Benz Group AG | 62 | |
| Harald Wilhelm | Mercedes Benz Group AG | 57 | |
| Christina Hickie | CSL Limited | N/A | |
| Susie Lisa | Vertex Pharmaceuticals Incorpor | N/A | |
| Noubar Afeyan | Moderna | 60 | |
| Tal Zaks | Moderna | 53 | |
| Monique Carter | Novo Nordisk AS | 50 | |
| Paul BA | CSL Limited | 66 | |
Management Performance
| Return On Equity | -0.45 | |||
| Return On Asset | -0.26 |
Cara Therapeutics Leadership Team
Elected by the shareholders, the Cara Therapeutics' board of directors comprises two types of representatives: Cara Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Cara. The board's role is to monitor Cara Therapeutics' management team and ensure that shareholders' interests are well served. Cara Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Cara Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Joana Goncalves, Chief Medical Officer | ||
| Christopher Posner, Director | ||
| Beth Weinberg, VP QA | ||
| Eric Vandal, VP Commercial | ||
| Frdrique Menzaghi, Chief RD | ||
| Iris Francesconi, Chief Relations | ||
| Scott Terrillion, Chief Compliance Officer, General Counsel, Secretary | ||
| Dr DSc, CoFounder Advisor | ||
| Ryan Maynard, Chief Officer |
Cara Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Cara Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.45 | |||
| Return On Asset | -0.26 | |||
| Profit Margin | (2.25) % | |||
| Operating Margin | (2.28) % | |||
| Current Valuation | 450.58 M | |||
| Shares Outstanding | 53.73 M | |||
| Shares Owned By Insiders | 16.10 % | |||
| Shares Owned By Institutions | 65.69 % | |||
| Price To Book | 3.33 X | |||
| Price To Sales | 14.36 X |
Currently Active Assets on Macroaxis
Other Information on Investing in Cara Stock
Cara Therapeutics financial ratios help investors to determine whether Cara Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Cara with respect to the benefits of owning Cara Therapeutics security.